Teva's ecopipam review highlights D1 receptor edge in Tourette tics
Teva Pharmaceuticals has announced the publication of a comprehensive review in the Journal of Child Neurology examining the role of dopamine pathways in Tourette syndrome and setting out the clinical rationale for ecopipam, its investigational selective D1 receptor antagonist. The review synthesises data from the company's D1AMOND development programme and positions the compound as a mechanistically distinct option from existing antipsychotic therapies in a condition that affects an estimated one in 130 children worldwide.
Ecopipam targets D1 receptors expressed primarily in the brain's direct motor pathway, where elevated dopaminergic activity in the basal ganglia is proposed to drive the involuntary motor and vocal tics that define Tourette syndrome. That stands in contrast to approved agents such as aripiprazole and haloperidol, which act on D2 receptors in the indirect pathway. Teva says the selectivity may translate into a more favourable side-effect profile, particularly the absence of clinically relevant weight gain, adverse metabolic effects and drug-induced movement disorders that can limit tolerability with D2-targeting therapies.
Clinical evidence
The review draws on data from two D1AMOND trials. The Phase 2b study, a 12-week randomised, double-blind, placebo-controlled trial enrolling 153 paediatric participants across 68 sites in North America and Europe, used change in the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS) as its primary endpoint. A 12-month open-label extension of the same cohort provided longer-term tolerability data. The Phase 3 D1AMOND trial, a randomised withdrawal design enrolling 216 participants in total, found that continued ecopipam treatment reduced the risk of tic relapse by 50% versus placebo in its paediatric subgroup (HR: 0.5; P=0.008). The most commonly reported adverse events were somnolence, headache, insomnia, fatigue and anxiety.
Real-world persistence figures cited in the review add context to those tolerability claims: among patients newly initiated on D2 receptor antagonists, 61.2% had discontinued by three months and 82.1% by 18 months, suggesting that the current standard of care carries a substantial adherence burden. Ecopipam has received Priority Review and Orphan Drug designation from the FDA for the paediatric Tourette indication, and Teva has filed an NDA seeking approval exclusively for that population.
Market and regulatory context
Tourette syndrome sits within a paediatric neurology landscape that has seen limited therapeutic innovation in recent decades. The three agents with an FDA-approved Tourette label, haloperidol (1969), pimozide (1984) and aripiprazole (2014), all target D2 pathways, and none were developed primarily for the condition. The Orphan Drug route Teva is pursuing carries a priority review voucher if approved, an asset with considerable secondary-market value given recent voucher transactions. The FDA's Priority Review designation shortens the standard review clock to six months, meaning a regulatory decision could follow within that window of NDA acceptance. A positive outcome would make ecopipam the first novel mechanism approved for Tourette syndrome in more than a decade and the first agent specifically designed to block D1 receptor signalling in any indication.
Donald Gilbert, senior author of the review and a paediatric movement disorder specialist at Cincinnati Children's Hospital Medical Center, said the data demonstrating reduced tic severity and sustained benefit "without significant weight gain, metabolic complications or movement disorders supports continued research into D1 receptor antagonism for Tourette syndrome."
The path from Priority Review to approval is not guaranteed, and Teva has not disclosed a PDUFA date in this announcement. Clinicians and investors will look to the full advisory committee process and any FDA information requests as the next meaningful milestones for the programme.